FDA lifts partial clinical hold on Gilead's magrolimab + azacitidine studies
Justin Sullivan/Getty Images News


Gilead Sciences (NASDAQ:GILD) on Monday announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold placed on studies evaluating its investigational agent magrolimab in combination with azacitidine.
Gilead said U.S. enrollment can resume for the studies investigating magrolimab in combination with azacitidine for the treatment of myelodysplastic syndrome and acute myeloid leukemia.

FDA's decision based on review of the comprehensive safety data from each trial.
The FDA had placed a partial clinical hold on the studies evaluating the combination of magrolimab with azacitidine in late January due to an apparent imbalance in suspected unexpected serious adverse reactions between study arms.
The company on Monday also said it is working with the FDA regarding the remaining partial clinical hold affecting studies evaluating magrolimab in diffuse large B-cell lymphoma and multiple myeloma.